Table 1:
Demographic, staging, and patient outcome information.
| Characteristics | Number of Cases | Percentage |
|---|---|---|
| Total Number | 32 | NA |
| Gender | ||
| Male | 12 | 37.5% |
| Female | 20 | 62.5% |
| Age ± SD (y) | 57.7 ± 14.0 | NA |
| Cohort | ||
| Yale | 7 | 21.9% |
| Karolinska | 25 | 78.1% |
| Tumor Size (cm) | ||
| Mean ± SD | 13.0 ± 4.4 | NA |
| Range | 5.5 – 21.0 | NA |
| ENSAT 2008 Stage | ||
| I | 0 | 0.0% |
| II | 16 | 50.0% |
| III | 9 | 28.1% |
| IV | 7 | 21.9% |
| Metastasis at | ||
| Presentation | 7 | 21.9% |
| Hormone Hypersecretion | ||
| Aldosterone | 1 | 3.1% |
| Cortisol | 8 | 25.0% |
| Androgen | 3 | 9.4% |
| Multi-secreting* | 5 | 15.6% |
| Non-functional | 11 | 34.4% |
| No information available | 4 | 12.5% |
| Outcome | ||
| Alive, no recurrence | 9 | 28.1% |
| Alive, recurrent | 3 | 9.4% |
| Death from disease | 16 | 50.0% |
| Death from other causes | 4 | 12.5% |
cm, centimeter; DHEA, dehydroepiandrosterone; ENSAT, European Network for the Study of Adrenal Tumors; SD, standard deviation; y, years.
*
Tumors secreting two or more of the following hormones: aldosterone, cortisol, testosterone, or DHEA.